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Abstract
In a seminal paper from 1990, Rosen and Bengtsson suggested that hypopituitary patients with a presumed growth hormone
(GH) deficiency (GHD) have an excess mortality. Later studies have confirmed this finding but have also shown that the cause of
the increased risk of death in these patients is multifactorial, including unreplaced GHD as well as non-physiological replacement
therapy of other deficiencies, the etiology of hypopituitarism, and the side effects of tumor treatment. Only a few studies have
investigated mortality in hypopituitary patients with GHD receiving GH replacement therapy (GHRT): these studies are retro-
spective observational studies with a wide range of underlying diseases but most of them show a mortality that is not different
from the general population. Even though the research field of survival in GHD patients with and without GHRT is lacking
prospective randomized trials, the evidence suggests that GHD in hypopituitary patients contributes to an excess mortality and
modern replacement therapy including GHRT will result in a mortality that is approaching normal. Herein, we review the
literature in the field of survival in GHD patients with and without GHRT. In addition, we outline the most important issues
when evaluating studies in this area.
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1 Introduction
Growth hormone (GH) deficiency (GHD) in adults is a well-
known entity for several decades. Early reports and hypothe-
ses on the effects of GHD in adults were already formulated at
the start of the 1960s [1, 2], but it was not until the availability
of recombinant human GH that the research field became
firmly established. Today, we know that adult GHD is char-
acterized by abnormal body composition, reduced muscle
strength and exercise capacity, reduced bone mass, an adverse
cardiovascular risk profile, and impaired quality of life [3, 4].
In a seminal article in 1990, Rosen and Bengtsson showed
that patients with hypopituitarism including an assumed
GHD, but substituted for all other deficiencies except GHD,
had an excess mortality [5]. This finding of excess mortality in
patients with unreplaced GHD has later been verified by sev-
eral studies [6, 7]. Hypopituitarism and its underlying causes
are complex and, today, it is believed that the reason for the
excess mortality is multifactorial including, for example, the
etiology of hypopituitarism, GHD, non-physiological
(glucocorticoid) replacement therapies, and tumor treatment
and its side effects [8–10]. This role for factors other than
GHD has been confirmed by the West Midlands Prospective
Hypopituitary Study, since it did not find an association be-
tween the degree of hypopituitarism and mortality but did find
an association with the risk factors mentioned above [10].
The effect of daily GH replacement therapy (GHRT) was
first shown in two placebo-controlled studies in 1989 [11, 12].
Since then, many studies have shown that long-term daily
GHRT ameliorates or reverses many of the effects of GHD,
including beneficial effects on muscle and fat mass, lipid pro-
file, diastolic blood pressure, and bone mass as well as improv-
ing quality of life [13–16]. A few retrospective observational
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studies have suggested that mortality is normalized in patients
with GHD receiving modern replacement therapy including
GHRT [17–19].
The effect of GHD on mortality is not as clear cut as once
perceived. In addition, data regarding the effect of GHRT on
mortality is still scarce. Therefore, the aim of this paper is to
review the effect of severe GHD and daily GHRT on survival
in adult patients.
2 GHD and mortality
The first study that demonstrated an excess mortality in adults
with hypopituitarism and presumed (untreated) GHD was pub-
lished by Rosen and Bengtsson in 1990 [5]. They studied 333
patients with hypopituitarism and compared mortality to that of
the general population. A total of 104 deaths were observed in
patients compared to 57.4 expected (P < 0.001), with women
tending to have a higher mortality than men. Mortality due to
vascular diseases was most common in patients (60 vs. 30.8
expected, P < 0.001), which was unrelated to sex, age, duration
of disease, radiotherapy, diabetes, blood pressure, or calendar
year of treatment. Patients treated for Cushing’s disease or ac-
romegaly were excluded because of their inherent excess mor-
tality. All patients were suspected as having GHD; however,
only 53 of the 333 were properly tested but, of these, all were
proven to have severe GHD. The authors’ hypothesis was that
the excess mortality was caused by untreated GHD.
Subsequently, four more studies have been published on this
issue, namely adult hypopituitarism including suspected GHD
and mortality (see Table 1) [6, 7, 10, 20].
Bates et al. [7] described a standardized mortality ratio
(SMR) of 1.73 (95% CI 1.28–2.18) in a cohort of 172 adult
patients with hypopituitarism caused by a variety of etiol-
ogies. Age and hypogonadism were important influencing
factors, with older and hypogonadal patients having lower
mortality. This study also described a sex difference for
all-cause mortality where women appeared to have a
higher mortality (SMR 2.29, 95% CI 1.37–3.58) compared
to men (SMR 1.50, 95% CI 1.02–2.13). Another, compa-
rable Swedish study [6] demonstrated similar results with
an increased overall mortality (SMR 2.17, 95% CI 1.88–
2.51) in 344 patients with hypopituitarism excluding pa-
tients with prior Cushing’s disease or acromegaly. This
study confirmed the higher mortality risk in women
(SMR 2.93, 95% CI 2.28–3.75 in women vs. 1.91, 95%
CI 1.59–2.28 in men). In particular, cerebrovascular mor-
tality was increased in this cohort compared to the general
population. For cerebrovascular mortality, women also had
a greater risk of death (SMR 4.91, 95% CI 2.62–8.40) than
men (SMR 2.64, 95% CI 1.44–4.42). Notably, almost all
patients (86%) were treated with radiotherapy in addition
to pituitary surgery.
In 2001, a large cohort study in 1014 patients with hypopi-
tuitarism by Tomlinson and colleagues [10] once again demon-
strated an excess mortality, which also was significantly higher
in women than in men. Due to the large cohort, they could
perform sub-analyses, which showed an increased mortality
risk for younger patients, patients with craniopharyngioma, pa-
tients treated with surgery or radiotherapy, and patients with
hypogonadism. The authors argued against an important role
for GHD in the increased mortality in hypopituitarism since the
degree of hypopituitarism was not related to the risk of death in
their study. However, GHD was not functionally tested in 89%
of the patients and is known to be one of the first deficiencies to
occur in pituitary insufficiency [21]. One of the last studies to
describe mortality in hypopituitarism without the influence of
GHRT is the study by Svensson and colleagues [20] in 2004.
This study underlined the increased mortality risk as previously
described. Of interest in their study was the relative high mor-
tality risk due to malignancies (SMR 3.92, 95% CI 3.21–4.76).
The authors hypothesized that the increased risk of death due to
malignancies was caused by radiotherapy, the presence of mul-
tiple endocrine neoplasia syndrome, or GHRT use in
childhood-onset hypopituitarism. Since no data was available
on these characteristics, we cannot compare it to earlier studies.
When interpreting the above mentioned studies, one should
realize that hypopituitarism and GHD are not synonymous.
Severe GHD was not properly diagnosed in most patients
and may not have been present in a small proportion of the
cohorts. More recently, two studies investigating the long-
term effect of GHRT have also presented mortality rates in
accurately diagnosed, but untreated, GHD patients (control
groups, not randomized) [18, 22]. The first to publish long-
term data from a national registry on GHRT and mortality was
van Bunderen and colleagues [18] in 2011. Their study
contained a small (n = 109), non-randomized, control group
of adult patients with severe GHD. The reason for not starting
GHRT was related to a serious comorbidity (including malig-
nancies and pituitary tumor recurrence) in only 12% of the
patients. Mortality, in this small group of patients, was not
significantly increased (SMR 1.42, 95% CI 0.79–2.56). In
2013, the US prospective, observational Hypopituitary
Control and Complication Study (HypoCCS) [22] sponsored
by Eli Lily and Company published data from their database,
which included 442 untreated GHD patients with a mean
follow-up of only 2.3 years. The frequency of mortality did
not differ significantly (P = 0.73) between the treated and un-
treated group (1.66% vs. 2.49%) after adjusting for baseline
differences. The SMR was not increased for the untreated
GHD group (SMR 0.58, 95% CI 0.29–1.04).
Interpreting the convincing excess mortality in the early
cohort studies on hypopituitarism and the mortality rates in
the later studies in patients diagnosed with GHD, one might
notice a decreasing excess mortality over time (Fig. 1). This
could be due to changes in other factors than GHD which can
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influence mortality such as better monitoring and treatment of
the pituitary disorders and its co-morbidities as well as im-
proved replacement therapy of the other anterior pituitary ax-
es, since the latter studies were published more than two de-
cades after the first study by Rosen and Bengtsson. However,
the improvement in survival over recent decades seems to be
small when looking at time trends of mortality in all patients
with non-functioning pituitary adenoma regardless of hypopi-
tuitarism, in Sweden [23]. Of course, selection bias cannot be
ruled out as it can influence the outcome in both directions.
Therefore, the above mentioned studies, although to be
interpreted with caution, do demonstrate a high likelihood
for a role of GHD in the excess mortality demonstrated in
adult patients with hypopituitarism.
3 GHRT and mortality
In 2004, the previous mentioned study by Svensson and col-
leagues [20] was the first to describe mortality risk in a small
cohort (n = 289) of properly diagnosed patients with severe
GHD from a single hospital with a mean treatment duration
of 5 years for GHRT. Mortality was not different from the
general population (SMR 0.84, 95% CI 0.36–1.66). The au-
thors suggested that GHRT reduced mortality in hypopituitary
patients, since their hypopituitary cohort without GHRT had a
highly increased risk of overall mortality (SMR 3.80, 95% CI
3.43–4.19). However, these two different cohorts were not
fully comparable, e.g. patients in the hypopituitary cohort
without GHRT was older at inclusion in the study compared
to patients in the GHRT cohort.
Later, in 2011, van Bunderen and colleagues [18] pub-
lished data on 2229 adult patients receiving GHRT from a
national registry in the Netherlands. They demonstrated a
slightly increased mortality compared to the background pop-
ulation (SMR 1.27, 95% CI 1.04–1.56), which was only in-
creased in women (SMR 1.66, 95% CI 1.23–1.78) and not in
men (SMR 1.06, 95% CI 0.81–1.40). The mortality, both in
the overall cohort and in both sexes, was mostly due to car-
diovascular diseases. Excluding patients with an inherent ex-
cess mortality risk (e.g. craniopharyngioma or possible malig-
nant cause of hypopituitarism) normalized the mortality,
which suggests that factors other than GHD/GHRT alone
can influence mortality risk. After the exclusion of high-risk
patients, the mortality risk due to cardiovascular disease
remained increased for women (SMR 2.36, 95% CI 1.43–
3.92). Gaillard and colleagues [24] reported the long-term
effect of GHRT from the KIMS (Pfizer International
Metabolic Database) database in 2012. They investigated
all-cause and cause-specific mortality in 13,983 patients and
also studied factors associated with mortality. In accordance
with previous studies in hypopituitary patients, female sex,
younger age at diagnosis, underlying diagnosis of
craniopharyngioma or aggressive tumor, presence of diabetes
insipidus, and pre-treatment with radiotherapy were all inde-
pendently associated with increased mortality. All-cause mor-
tality was elevated in women (SMR 1.56, 95% CI 1.36–1.78),
but not in men (SMR 0.94, 95% CI 0.84–1.06). Subsequently,
Burman et al. [25] investigated the causes of death in more
detail among the 1286 Swedish patients registered in the
KIMS database. They found an increased mortality, which
was not only accounted for by an excess in cardiovascular
mortality but also due to infections and suspected inadequate-
ly treated hypocortisolism during stress (based on a small
number of patients, n = 8). In 2014, Tritos et al. [26] presented
mortality data for a subgroup of patients from the KIMS
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Fig. 1 All-cause mortality in studies on hypopituitarism with or without
growth hormone replacement therapy (GHRT). Data are given as
standardized mortality ratios (SMRs) with 95% confidence intervals
(CIs) and numbers of observed (Obs.) and expected (Exp.) deaths for
studies with GHRT (upper) and without (lower) GHRT. *For Rosen &
Bengtsson only the observed and expected number of deaths are given
together with the ratio since no confidence interval was presented in this
study
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database. They compared 164 patients with a diagnosis of
GHD and acromegaly and 2467 patients with a diagnosis of
GHD and non-functioning pituitary adenoma. The SMR in the
GHD patients with acromegaly was 1.32 (95% CI 0.70–2.25).
Surprisingly, the SMRwas lower in GHD patients with a non-
functioning pituitary adenoma than for the general population
(SMR 0.58, 95% CI 0.48–0.94). The decreased mortality
compared to the general population could be the effect of the
close surveillance of these patients.
The sponsored prospective safety surveillance database,
the HypoCCS, published their mortality data in 2013 [22].
They found a lower mortality in patients with GHRT com-
pared to an untreated control group (not statistically signifi-
cant after adjusting for baseline differences) and an SMR of
0.86 (95% CI 0.59–1.21) compared to the US general popu-
lation, although the mean follow-up period was limited to
2.3 years. In 2014, Stochholm and colleagues (19) retrospec-
tively studied the impact of socioeconomic factors on mortal-
ity in patients with adult GHD. Of the 276 patients, only 133
received GHRT and they had a decreased mortality risk com-
pared to untreated patients (hazard ratio 0.34, 95% CI 0.15–
0.77) even after adjustment for all measured confounders.
Olsson and colleagues [17] studied a homogenous group of
patients with only one underlying cause of GHD, a non-
functioning pituitary adenoma. They found a significantly
lower mortality (SMR 0.65, 95% CI 0.44–0.94) in the 207
patients treated with GHRT. This was also significantly lower
compared to the control group of 219 patients with non-
functioning pituitary adenoma who did not receive GHRT
(not randomized). This was the first non-registry, single-
center study to investigate GHRT in a single underlying eti-
ology of GHDwithout an inherent excess mortality risk. Also,
the follow-up duration was extensive, with a median GHRT
duration of 12 years. Nevertheless, selection bias for those
who received GHRT cannot be excluded. Table 2 shows an
overview of the cited studies on GHRT and mortality.
When interpreting the effect of GHRT on mortality
(Fig. 1), one must remain critical. A number of prospective,
randomized, placebo-controlled trials have suggested that,
compared to placebo, GHRT has improved the detrimental
effects of hypopituitarism attributed to GHD, but not in all
[27]. This is in line with the results from many non-
controlled retrospective and open-label observational studies
[14], including most of the above-mentioned studies on sur-
vival. While placebo-controlled trials are challenging to com-
plete in small patient populations, these trials nevertheless
provide data with fewer confounders compared to open-label
studies. Although comparisons with the background popula-
tions were corrected for age, sex, and calendar year in the
mentioned retrospective cohort studies, an effect of factors
other than GHRT cannot be ruled out. The association of
mortality in hypopituitarism with confounding variables, such
as younger age, sex, surgery or radiotherapy, or the underlying
condition such as craniopharyngioma is also demonstrated in
adults with GHD receiving GHRT. We earlier concluded that
the increased mortality in hypopituitarism may be multifacto-
rial and, therefore, not attributable to GHD alone. Thus,
GHRT does not ameliorate al l of the aspects of
hypopituitarism/pituitary disease, but it does explains a pro-
portion of the improved, but not always normalized, mortality
risk.
4 Shortcomings of studies investigating
mortality in GHD and GHRT
Several aspects need to be considered when evaluating mor-
tality in patients with GHD that have or have not received
GHRT (Table 3). There is a large variety of different under-
lying diseases causing hypopituitarism. Some of these under-
lying diseases (e.g. non-functioning pituitary adenoma) entail
no excess mortality, whereas some (e.g. craniopharyngioma)
result in a large excess mortality no matter whether they have
GHDwith or without GHRT [9, 24, 28]. The large majority of
studies investigating mortality in GHD patients with and with-
out GHRT have a combination of patients with both low and
high inherent risk of excess mortality [10, 18, 19], which will
affect the outcome.
A similar issue needs to be considered when investigating
patients with different types of pituitary tumor treatments. For
instance, treatment with radiotherapy can be related to an in-
creased risk of death either because of a more severe underly-
ing pituitary disease, needing a more aggressive treatment
regime, or due to side effects of the treatment itself (for exam-
ple, radiotherapy is associated with a risk of secondary brain
tumors) [24, 29].
Pituitary diseases and its consequences, including hypopi-
tuitarism, lead to multiple treatment challenges. Many of
them, such as glucocorticoid replacement, can also affect the
mortality in patients with hypopituitarism [8]. In addition,
almost all patients receiving GHRT are followed closely at
specialized units that not only manage their GH substitution
but also perform frequent overall health examinations. The
close follow-up of these patients compared to the general pop-
ulationmight be an advantage with respect to the development
of, for example, type 2 diabetes mellitus or decreasing the
frequency of negative behaviors, such as smoking. This could
result in a surveillance bias for the group of patients with
GHRT.
Furthermore, in some of the initial studies on mortality in
patients with hypopituitarism and GHD, no formal testing for
severe GHD diagnosis was performed in the majority of pa-
tients (5, 7, 10). Even though deficiency in the somatotropic
axis is, in many cases, one of the first deficiencies in hypopi-
tuitarism, hypopituitarism and GHD are not synonymous [21].
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This means that severe GHD might not have been present in
all patients with hypopituitarism.
A more general issue that needs to be taken into account is
the problem with short follow-up, low number of events, and/
or potential selection bias in (retrospective) observational co-
hort studies. The follow-up needs to be sufficient to be able to
predict the mortality in a chronic treatment modality, like
GHRT [22]. Also, few events in a study brings uncertainty
to the results and makes it impossible to properly control for
multiple confounders [20]. Finally, there is always a potential
selection bias in studies without randomization.
Considering all of the above-mentioned aspects (Table 3),
the effect of each factor on outcome is hard to predict. Many
of the studies on hypopituitarism and GHD or GHRT include
patients with an inherent excess mortality risk which might
overestimate mortality compared to a general population and
underestimate the effect of GHRT. In studies on GHRT, po-
tential selection bias, on the other hand, could underestimate
the mortality risk.
5 Future challenges and questions
5.1 Future challenges
& No randomized trial has been performed to investigate
either the effect of GHD or GHRT on mortality.
Unfortunately, it would be an enormous task to perform
such a study and it is questionable whether it would be
ethical to withhold GHRT during long-term follow-up
given the verified positive effects on aspects other than
mortality.
& The beneficial effect of GHRT has been extensively dem-
onstrated, but data in elderly patients with GHD is scarce
[30]. It would be of interest to formally investigate the
effects, including mortality, of long-term GHRT in older
patients (over 60 years of age) with hypopituitarism and
severe GHD.
5.2 Questions
& The available evidence suggests that the mortality in adult
patients with hypopituitarism including GHD is ap-
proaching normal in patients receiving modern replace-
ment therapy including daily GHRT. Will this be similar
for long-acting GHRT?
& Many of the studies investigating hypopituitarism includ-
ing GHD as well as replacement with GH demonstrate a
remarkable sex difference in (cardiovascular) mortality.
What is the explanation for the higher (cardiovascular)
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6 Conclusion
Several studies from the 1990s demonstrated an excess mor-
tality in patients with hypopituitarism including a presumed or
verified GHD. It was then suggested that the increased risk of
death originated from the unreplaced GHD. Today, evidence
suggests that the excess mortality in these patients has multi-
ple causes, including not only the unreplaced GHD but also,
for example, the etiology of hypopituitarism, non-
physiological glucocorticoid replacement therapy as well as
tumor treatment and its side effects.
The majority of studies on mortality in hypopituitary pa-
tients receiving GHRT show a normal risk of mortality com-
pared to the background population. However, since the cause
of the excess mortality in hypopituitary patients is multifacto-
rial, the improvement also emanates from factors other than
GHRT, such as advances in the treatment of other deficiencies
and of the pituitary tumor.
Themost important limitation of the literature in the field of
survival in GHD patients with or without GHRT is the lack of
prospective, randomized trials. Since a prospective, random-
ized trial would be a tremendous undertaking, and it could
also be ethically questionable to let GHD patients go untreated
for a long period of time, it is unlikely that we will ever see
such a trial.
In conclusion, the evidence available to date suggests that
GHD in patients with hypopituitarism contributes to an excess
mortality and that modern replacement therapy including
GHRT in these patients has resulted in a mortality that is
approaching normal.
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Table 3 Aspect that needs to be considered when evaluating studies on mortality in patients with GH deficiency that have or have not received GHRT
Factor Example reference Description
Risk of inherent excess mortality
(underlying disease causing
hypopituitarism)
Gaillard et al. [24] Some of these underlying diseases (e.g. non-functioning pituitary
adenoma) have no excess mortality, whereas some (e.g.
craniopharyngioma) have a large excess mortality. In studies
with a combination of patients with both low- and high-inherent
risk of excess mortality, this factor will have an effect on the
outcome.
Risk of inherent excess mortality
(pituitary tumor treatments)
Stochholm et al. [19] For example, treatment with radiotherapy can be related to excess
mortality either because of a more severe underlying pituitary
disease, needing a more aggressive tumor treatment, or due to
side effects of the treatment itself.
Other aspects of hypopituitarism Burman et al. [25] Hypopituitarism often includes multiple deficiencies. Many of
them, e.g. glucocorticoid replacement, can also affect the
mortality in patients with hypopituitarism.
Potential surveillance bias Olsson et al. [17] Themajority of all patients treated with GH are followed closely at
specialized units. The close follow-up of these patients
compared to the general population might be an advantage with
respect to the development of (e.g. hypertension) or decreasing
the frequency of negative behaviors (e.g. frequent alcohol
intake).
Potential selection bias Hartman et al. [22] In observational cohort studies without randomization, there is
always a potential selection bias.
Short follow-up/low number of events Tritos et al. [26] The follow-up needs to be sufficient to be able to predict mortality
in a chronic treatment modality, like GHRT. In addition, few
events in a study bring uncertainty to the results and makes it
hard to properly control for multiple confounders.
GH: growth hormone; GHRT: growth hormone replacement therapy
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